Since E7449, a dual inhibitor of PARP 1/2 and TNKS, is the only drug currently under clinical trials, TNKS inhibitors need to be continuously developed and studied as anticancer drugs to elucidate the biological aspects of cancer cells [22]. This evidence concerns the gene TNKS and cancer.